Clinical Trials - April 14, 2016
Positive results for Novo Nordisk’s Saxenda
Novo Nordisk’s Saxenda demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo. New data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016). The three-year part of […]
Clinical Trials - May 11, 2015
Saxenda Benefits Beyond Weight Loss
New data from a post-hoc analysis of the phase 3a SCALE™ clinical trial program were presented at the European Congress on Obesity (ECO), demonstrated that Novo Nordisk’s Saxenda (liraglutide 3 mg) has benefits beyond weight loss. “…The post-hoc analysis confirmed that weight loss has a positive impact on a number of cardiometabolic risk factors, including […]
Drug Development Pharma - March 24, 2015
EC Approves Weight-Loss Drug
The European Commission has granted marketing authorization for Novo Nordisk’s Saxenda® (liraglutide 3 mg) for the treatment of obesity. The authorization covers all 28 European Union (EU) member states. Saxenda® is the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity approved in Europe. Saxenda® is prescribed as a supplement to a reduced-calorie diet and increased physical […]
Drug Development Pharma - March 10, 2015
Health Canada OKs Weight Drug
Health Canada has approved the new drug submission for Novo Nordisk’s Saxenda® (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of chronic weight management. Saxenda® is an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in obese adults and overweight adults with at least one […]
New Market - January 27, 2015
Novo to Market Saxenda in U.S.
Novo Nordisk plans to put 500 U.S. sales reps, or about one-sixth of that country’s sales force, to work marketing its newly-approved weight-loss drug Saxenda, a reformulated version of diabetes drug Victoza (liraglutide). In an interview with the Financial Times, Novo Chief Science Officer Mads Krogsgaard Thomsen said his company is looking to generate at […]
Drug Development Pharma - January 23, 2015
Novo’s Saxenda Gets Approval
The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive ruling for the use of Novo Nordisk’s Saxenda® (liraglutide 3 mg) in the treatment of obesity, according to a statement from the company. The CHMP recommends that Saxenda® be prescribed as an adjunct to a reduced-calorie diet and increased […]
